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Immune checkpoint therapy, which can target regulatory
pathways of T cells to enhance antitumor immune
responses, has led to important clinical advances and
provides novel strategies for combination immunothera-
pies against cancer. ALT-803 is an IL-15 superagonist
complex capable of stimulating T cell and NK cell
responses without triggering Treg activity. ALT-803
exhibits improved pharmacokinetics and lymphoid
organ biodistribution compared to native IL-15, allowing
this complex to have more potent efficacy against var-
ious hematologic and solid tumor models. Antibodies
that block checkpoint inhibitor interactions, such as
PD-1/PD-L1 or CTLA-4, have shown clinical efficacy
against both melanoma and lung cancer, and may also
be active in other tumor types, including bladder cancer.
Here, we report that the combination of immune check-
point blockers with ALT-803 has potent anti-tumor
activity in C57BL/6 mice bearing syngenic orthotopic
MB49-luc bladder tumors. These tumor cells were
found to express CTLA-4 ligands and PD-L1 on the cell
surface; thus, blockade of both CTLA-4 and PD-1/PD-
L1 pathways were evaluated. Treatment of mice bearing
established MB49luc bladder tumors with ALT-803
monotherapy exhibited a statistically significant increase
in survival compared to controls (P < 0.05). However,
the combination of ALT-803 with anti-PD-L1 and anti-
CTLA-4 Abs further prolonged survival compared to
control or related monotherapies. This effect was also
seen with combination therapy of ALT-803+anti-PD-1
and ALT-803+anti-PD-1/anti-CTLA-4 Abs. Additionally,
mice that were cured of MB49-luc tumors by ALT-803
plus anti-PD-L1/anti-CTLA-4 Ab therapy were resistant
from bladder tumor rechallenge without further drug
treatment whereas age-matched treatment-naïve mice
developed tumors and die following MB49-luc tumor
cell instillation. These results demonstrate that a short
course of ALT-803 plus immune checkpoint inhibitor
treatment not only has potent efficacy against estab-
lished MB49luc tumor, but is also capable of inducing
long-lasting protective immunologic memory against
subsequent tumor cell rechallenge. Characterization of
immune cell activity responsible for improved antitumor
efficacy is underway. Overall, these results confirm that
enhanced antitumor responses can be achieved by com-
bining immune checkpoint blockers with the immunos-
timulatory agonist ALT-803, warranting evaluation of
these strategies in the clinical setting.
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